[ * ] = CERTAINCONFIDENTIALINFORMATIONCONTAINEDINTHISDOCUMENT,MARKEDBYBRACKETS,HASBEENOMITTEDANDFILEDSEPARATELYWITHTHE SECURITIESAND EXCHANGE COMMISSIONPURSUANTTO RULE 24B-2OFTHE SECURITIES EXCHANGE ACTOF 1934,ASAMENDED.
Exhibit 10.43
Chris Penland, Ph.D.
Cystic Fibrosis Foundation Therapeutics, Inc.
6931 Arlington Road
Bethesda, MD 20814
Dear Dr. Penland:
The purpose of this letter agreement is to amend the Study Funding Agreement, dated June 17, 2003, as amended, between the undersigned parties (the “Agreement”). By signing below, the undersigned parties agree to hereby amend the Agreement as follows:
1. | In Section 2.2 of the Agreement, the Work Plan shall be amended to include the following: |
a. | “Performing pre-clinical animal experiments in a mouse model of cystic fibrosis, and |
b. | Performing a phase I safety study in cystic fibrosis patients.” |
2. | In Section 8.1(c) of the Agreement,[ * ]shall be replaced with[ * ]. |
3. | Exhibit B of the Agreement shall be replaced in its entirety with the attached Exhibit B. |
All other terms and provisions of the Agreement shall remain unchanged and are in full force and effect.
HOLLIS-EDEN PHARMACEUTICALS, INC. | ||
By: | /s/ E. Loumeau | |
Eric J. Loumeau Vice President, General Counsel | ||
Agreed to and Acknowledged by: | ||
CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. | ||
By: | /s/ R. Beall | |
Robert J. Beall, Ph.D. President and CEO |
[ * ] = CERTAINCONFIDENTIALINFORMATIONCONTAINEDINTHISDOCUMENT,MARKEDBYBRACKETS,HASBEENOMITTEDANDFILEDSEPARATELYWITHTHE SECURITIESAND EXCHANGE COMMISSIONPURSUANTTO RULE 24B-2OFTHE SECURITIES EXCHANGE ACTOF 1934,ASAMENDED.
EXHIBIT B
BUDGET
Total Budget: $1,700,000.00
To be paid as follows:
[ * ]
Payments will be made via express mail by check payable to:
Hollis Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, CA 92121
Attn: | Robert Weber |
Phone: 858-587-9333
Tax ID all other: